As per this study the Global Thalassemia Treatment Market was valued USD XX MN (by revenue) in 2019 and is anticipated to reach USD XX MN by 2026 with a CAGR of XX%.
Thalassemia is the genetic blood disease that affects the production of red blood cells (RBCs) and hemoglobin. It can be characterized by pale skin, headache, fatigue, leg cramp, and rapid heartbeats. Thalassemia can be treated by frequent blood transfusion, iron chelation, stem cell transplant, nutritional supplements, and gene therapy.
Rising occurrence of thalassemia with growing awareness to treat thalassemia is driving the market growth. The rise in healthcare expenditure with the growing popularity of gene therapy is further expected to support market growth in the forecast period. Further, rising clinical trails for the development of novel therapies is expected to upsurge the growth of thalassemia treatment market. However, the high cost of the treatment may act as a challenge to market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of thalassemia treatment.
The broad thalassemia treatment market has been sub-grouped into type, class and end-user. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
- Alpha Thalassemia
- Beta Thalassemia
- Iron Chelating Drugs
- Gene Therapy
- Research Institute
Furthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for thalassemia treatment in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Europe Thalassemia Treatment Market By Revenue (USD MN)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the thalassemia treatment market include Acceleron Pharma, Inc., Bluebird Bio, Inc., GlaxoSmithKline plc., Incyte Corporation, IONIS Pharmaceuticals, Kiadis Pharma, La Jolla Pharmaceutical Company, Lonza Group Ltd. and Sangamo Bioscience among others. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.